DecisionDx-Melanoma 31-Gene Expression Profile Test Stratifies Patients With Cutaneous Melanoma
Source: OncLive, July 2023
The DecisionDx-Melanoma 31-gene expression profile test displayed the capability to stratify patients with cutaneous melanoma by risk of death from the disease and receival of the 31-GEP test may result in a survival benefit compared with untested patients.
The DecisionDx-Melanoma 31-gene expression profile (31-GEP) test displayed the capability to stratify patients with cutaneous melanoma by risk of death from the disease and receival of the 31-GEP test may result in a survival benefit compared with untested patients, according to findings published in the Journal of Clinical Oncology.
The validated GEP test classifies the risk of recurrence, metastasis, or death for patients with melanoma as either low (class 1A), intermediate (class 1B/2A), or high (class 2B).1 It is RT-PCR–based and usesformalin-fixed paraffin-embedded primary tumor tissue to determine which classification a given patient falls into based on expression of 31 genes.